Lawson Lundell Advises Roivant Sciences Ltd. on Closing of Second Tranche of a $116M Strategic Investment in Arbutus Biopharma Corporation


On January 12, 2018 Arbutus Biopharma Corporation (“Arbutus”), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, closed on a transaction involving the issue and sale of 664,000 series A participating convertible preferred shares of Arbutus (Preferred Shares) to Roivant Sciences Ltd. (“Roivant”) for gross proceeds to Arbutus of US$66.4 million (Tranche 2). The Tranche 2 closing represents the second of two tranches of Preferred Shares issued to Roivant and, together with the previously announced Tranche 1 closing on November 7, 2017, comprise the previously announced US$116.4 million strategic investment by Roivant in Arbutus. Lawson Lundell LLP acted as lead Canadian counsel for Roivant with a team led by Valerie Mann and Crispin Arthur.

Jump to Page